Major news broke in the iPSC sector last week when Ncardia (Cologne, Germany) and Nanion Technologies (Munich, Germany) signed a joint marketing and sales promotion agreement. Under the terms of partnership, customers of the companies will get access to high-performance instrument platforms from Nanion, coupled with Ncardia’s portfolio of hiPSC-derived cardiac cell types and assay services. [Read more…]
Ncardia to Host U.S. User Symposium (June 13-14, Boston)
On June 13-14, 2018, in Boston, Massachusetts, Ncardia will host its Annual U.S. User Symposium. The event will showcase the use of Ncardia’s flagship hiPSC-derived cardiac models (Cor.4U® and Pluricyte®) and its hiPSC-derived neural cell products by key leaders in pharma and research.
Importantly, it will explore how experts in the pharmaceutical and biotechnology industry and leading academic institutions are using Ncardia’s first in class cells and assays in drug discovery, safety and toxicology screening, disease modelling and bioengineering. It will also present current approaches to establish and define standards for these cellular models.
Expected to be widely attended by representatives from the pharmaceutical sector, symposium attendees will view case studies of iPS cells in drug development decision-making and biomedical research and have the opportunity to exchange and share experiences with their peers.
ACEA Biosciences and Ncardia Partner to Provide Solutions for Cardiac Drug Discovery and Cardiac Safety Assessment
Ncardia Signs License Agreement with Roche for Disease Modeling Patent Portfolio
Ncardia Signs License Agreement with First Pharmaceutical Partner for Disease Modeling Patent Portfolio
October 12, 2017, COLOGNE, Germany–Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate companies gain access to key disease modeling patents from Ncardia.
Ncardia was recently formed through the merger of Axiogenesis and Pluriomics. The two companies have pioneered the development of stem cell derived cells for drug discovery and safety and in particular have advanced disease and tissue modeling applications.
The Ncardia patent portfolio consists of several granted patents in Europe, the USA and Japan. The drug screening and disease modeling technology not only involves patient iPSC cells, induction of the disease phenotype can also be achieved through genetic manipulation, mRNA or siRNA transfection or through chemical or physical induction. [Read more…]
NCardia, a Global Force in hiPSC Drug Discovery and Development Products and Solutions
Axiogenesis AG and Pluriomics B.V. are combining forces to form Ncardia, the new global authority in cardiac and neural applications of human induced pluripotent stem cells (iPSCs).
Founded in 2001, Axiogenesis AG has Cologne (DE) and Philadelphia (USA) facilities, while Pluriomics B.V. has facilities in Gosselies (BE) and Leiden (NL). By entering into this merger, these European leaders will become the global leader in hiPSC drug discovery and development field, making Ncardia the partner of choice for scientists conducting cardiovascular and neural safety and efficacy projects.
By combining their global client base, the merger of Axiogenesis and Pluriomics will position Ncardia as a leader in standardized, validated iPSC assays for safety, phenotypic screening and disease modelling. For scientists conducting cardiovascular and neural safety and efficacy projects, Ncardia will provide tools to facilitate accelerated development of drugs, while replacing animal studies and putting a “human” aspect back into drug discovery.
According to Felix Haniel, VP Business Development & Sales of Ncardia: “Our vision is to develop products and services that are a complete solution. We will produce human iPSC derived cardiovascular and neuronal cell types and realize validated electrophysiology, biochemistry and contraction based assays. By combining over two decades of experience, Ncardia will offer iPSC assays for safety pharmacology, toxicology testing, drug efficacy screening, phenotypic screening, and disease modelling.”
Founded in 2001 as a spin-off of the University of Cologne, Axiogenesis initially focused on generating mouse embryonic stem cell derived cells and assays. After Yamanaka’s groundbreaking iPSC technology became available, Axiogenesis was the first European company to license and adopt Yamanaka’s iPSC technology in 2010. Now Axiogenesis specializes in human induced pluripotent stem cell products, including in vitro models of healthy and diseased cell types and tissues. In 2014, Axiogenesis founded its American subsidiary in Philadelphia, PA. [Read more…]
